Sponsor Directory

Genentech, Inc. clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1396

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Myelodysplastic Syndrome (MDS)
Interventions: Venetoclax, Azacitidine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 58
States / cities: Fullerton, California • Los Angeles, California • Torrance, California + 50 more

Conditions: Non-small Cell Lung Cancer
Interventions: Atezolizumab, Tiragolumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 11
States / cities: Tempe, Arizona • Fort Myers, Florida • St. Petersburg, Florida + 8 more

Conditions: Ocular Cicatricial Pemphigoid
Interventions: Rituximab; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
Interventions: Atezolizumab, Sacituzumab govitecan; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: San Francisco, California • Chicago, Illinois • New Lenox, Illinois + 4 more

Conditions: Asthma
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Myeloma
Interventions: P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate; Biological · Drug
Lead sponsor: Poseida Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2042
U.S. locations: 23
States / cities: Goodyear, Arizona • San Diego, California • San Francisco, California + 19 more

Conditions: BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
Interventions: Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Vemurafenib; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Atezolizumab, Stereotactic radiosurgery (SRS); Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer)
Interventions: Epacadostat, Atezolizumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 6
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 2 more

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Polatuzumab vedotin (PV), Rituximab, Hyaluronidase, Gemcitabine, Cisplatin, Dexamethasone, GCSF; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pleural Effusion
Interventions: normal saline, TNK (Tenecteplase); Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Salivary Gland Cancer, HER2 Gene Mutation
Interventions: Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 13
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 8 more

About this Genentech, Inc. sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Genentech, Inc. is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Genentech, Inc. trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Genentech, Inc. clinical trials

Filter and sort this sponsor

Live official records

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Mechanisms of Acute Asthma Exacerbations Through Molecular Analysis of Airway Secretions and Tissues

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

About this Genentech, Inc. sponsor directory page